baha the information company baha WebStation Terminal contact us Request free demo

baha is a leading provider of real-time market data, financial news, technology and solutions for the financial industry. baha offers real-time data terminals for professionals, global financial market data covering over 12 million financial instruments on more than 150 exchanges, as well as 24/7 breaking news with global coverage and free web and mobile apps. From a total of around 200 real-time data providers worldwide, only Reuters 1851, Bloomberg 1981 and now baha in 2021 were named after the founder.

Free License - non-commercial use only

Region

Time Zone

International
history
open
Sign Up / Login

For full-featured experience, please enable JavaScript.

HSBC Knock-Out MOR/ DE000HS4GY28 /

2024-10-11 6:12:25 PM	Chg.0.00	Bid10:00:36 PM	Ask10:00:36 PM	Underlying	Strike price	Expiration date	Option type
2.96EUR	0.00%	- Bid Size: -	- Ask Size: -	MORPHOSYS AG O.N.	38.7734 EUR	2078-12-31	Call

GlobeNewswire 07-16 SHAREHOLDER ALERT: The M&A Class Action Firm Investigates Tender Offer Expiring August 2, 2024, of M...

TeleTrader 04-11 Novartis launches offer for Morphosys at €68 per share

TeleTrader 03-12 Germany clears Novartis' MorphoSys $2.9B deal

TeleTrader 02-05 Novartis to acquire MorphoSys for $2.9B

GlobeNewswire 2021-08-11 Royalty Pharma Reports Second Quarter 2021 Results

GlobeNewswire 2021-06-03 CONSTELLATION ALERT: Bragar Eagel & Squire, P.C. Investigates Sale of CNST and Encourages Investors ...

GlobeNewswire 2021-06-02 Royalty Pharma Announces $2.025 Billion Strategic Funding Partnership With MorphoSys

GlobeNewswire 2020-04-27 I-Mab and MorphoSys Announce First Patient Dosed in Phase 3 Clinical Trial of TJ202/MOR202 in r/r Mu...

GlobeNewswire 2019-10-28 MOR106 clinical development in atopic dermatitis stopped for futility

GlobeNewswire 2019-04-23 Galapagos and MorphoSys announce initiation of GECKO Phase 2 study with MOR106 in atopic dermatitis ...

GlobeNewswire 2019-04-23 Galapagos and MorphoSys announce initiation of GECKO Phase 2 study with MOR106 in atopic dermatitis ...

GlobeNewswire 2019-01-31 Genmab Announces that the Patent Infringement Lawsuit Relating to DARZALEX® is Over

GlobeNewswire 2018-09-13 Galapagos and MorphoSys announce start of a Phase 1 subcutaneous bridging study with MOR106

GlobeNewswire 2018-09-13 Galapagos and MorphoSys announce start of a Phase 1 subcutaneous bridging study with MOR106

GlobeNewswire 2018-09-12 MorphoSys and Galapagos announce U.S. Antitrust Clearance for global license agreement for MOR106 wi...

GlobeNewswire 2018-09-12 MorphoSys and Galapagos announce U.S. Antitrust Clearance for global license agreement for MOR106 wi...

GlobeNewswire 2018-07-19 MorphoSys and Galapagos Sign Global License Agreement for MOR106 with Top Pharma Partner

GlobeNewswire 2018-07-19 Novartis demonstrates commitment to lead immuno-dermatology by in-licensing IL-17C compound for atop...

GlobeNewswire 2018-07-19 MorphoSys and Galapagos Sign Global License Agreement for MOR106 with Top Pharma Partner

GlobeNewswire 2018-05-01 Galapagos and MorphoSys announce initiation of the IGUANA Phase 2 clinical trial with MOR106 in atop...

GlobeNewswire 2018-05-01 Galapagos and MorphoSys announce initiation of the IGUANA Phase 2 clinical trial with MOR106 in atop...

GlobeNewswire 2018-04-19 Nasdaq Welcomes MorphoSys AG (Nasdaq: MOR) to The Nasdaq Stock Market

GlobeNewswire 2018-02-17 Galapagos and MorphoSys present results from a Phase 1 study with MOR106 in atopic dermatitis as lat...

GlobeNewswire 2018-02-17 Galapagos and MorphoSys present results from a Phase 1 study with MOR106 in atopic dermatitis as lat...

GlobeNewswire 2017-09-27 Galapagos and MorphoSys report first promising signs of clinical activity in a Phase 1 study with IL...